Alistair Roddick

Academic Clinical Fellow in Nephrology, Oxford. Meta-analysis, trials, and kidneys. Views my own.

[NEJM @NEJM]

Presented at #ERA24:

FLOW trial: In patients with type 2 diabetes and chronic kidney disease, weekly semaglutide significantly reduced risks of major kidney events, cardiovascular events, and death from any cause while slowing loss of kidney function. https://t.co/Q9DAA6mPte

[JASN_News @JASN_News]

CKD is associated with fluid excess. This study found in patients with CKD, empagliflozin resulted in a sustained reduction in a bioimpedance-derived estimate of fluid overload, with no significant effect on fat mass https://t.co/y11gRuL1hs

@MartinLandray @Oxford_NDPH

[Will Herrington @willkidney]

2x key EMPA-KIDNEY papers exploring effects by uACR, eGFR, type of diabetes & primary kidney disease in @TheLancetEndo. Core Dec 2023 open access reading b4 you start your Xmas novel! (some of the most informative data on #SGLT2i in non-albuminuric #CKD…)🌲🎁 from @Oxford_NDPH

[Will Herrington @willkidney]

⁦@UKKidney⁩ Association Guideline: SGLT2 inhibition in Adults with Kidney Disease 2023 UPDATE in BMC Nephrol. Hard work+++ from ⁦@AndrewFrankel1⁩ ⁦@ajroddick⁩ and the dedicated working group. Useful patient info leaflets part of outputs. https://t.co/xz1u5ZKJ4i

[The UK Kidney Association @UKKidney]

Seeking guidance on #SGLT2 Inhibition in Adults with #Kidney Disease? Look no further!

Our new interactive website offers a user-friendly platform for healthcare providers, bringing the latest scientific evidence to your fingertips. #Guidelines

🔗https://t.co/XrxORBqxwP

[Will Herrington @willkidney]

⁦Professor @RichardHaynes3⁩ ‘s inaugural lecture ⁦@Oxford_NDPH⁩ - why we cannot just adjust away confounding! (Very funny & very serious!)

[The Lancet @TheLancet]

Sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of adverse kidney and #cardiovascular outcomes in patients with heart failure or chronic #kidneydisease, but the influence of #diabetes on the effects of SGLT2 is unclear.

[Will Herrington @willkidney]

#NephJC it is arguably not just down to an eGFR of 20 (see this post-hoc analysis of 254 patients with eGFR 15-20!)

[Brendon Neuen @brendonneuen]

Our SGLT2 Trialists Consortium meta-analysis *the largest ever* in @TheLancet

https://t.co/YlWkRQTDAW

Definitive evidence that SGLT2i ⬇️:
- Kidney failure
- AKI
- CV death
- All-cause death

Regardless of diabetes

Led by @NatalieStaplin @RichardHaynes3 @willkidney

#AHA22

[NEJM @NEJM]

In this trial involving patients with chronic kidney disease, empagliflozin resulted in a lower risk of disease progression or death from cardiovascular causes than placebo. #KidneyWk https://t.co/HFgzPgrRFx

[Brendon Neuen @brendonneuen]

SGLT2 inhibitors reduce CKD progression by ~40%, regardless of:

- Diabetes
- CKD aetiology
- Type of glomerular disease

And reduces AKI by ~20%

Presented by @NatalieStaplin on behalf of @Oxford_NDPH Renal Studies Group & SGLT2 Trialists Consortium (SMART-C)

#KidneyWk

[Oxford Population Health (OxPop) @Oxford_NDPH]

Going to @ASNKidney #KidneyWk?

Make sure to catch @willkidney and @RichardHaynes3's presentation on 'Empagliflozin in Patients With Chronic #KidneyDisease'

📅 4 November
⌚ 12:15 ET
Room: W415 Valencia

https://t.co/142HxFA1ZF

[The Lancet @TheLancet]

NEW—#Statins do not commonly cause muscle pain, confirms a new analysis published in The Lancet and presented at #ESCCongress today: https://t.co/I7yr1NGGWQ

[Martin Landray @MartinLandray]

EMPA-KIDNEY trial of empagliflozin in patients with chronic kidney disease will stop early due to evidence of efficacy following pre-specified assessment by independent Data Monitoring Committee

Excellent work @willkidney @RichardHaynes3 & colleagues

https://t.co/mtXOeYCEAe

[Martin Landray @MartinLandray]

One of the great letters.
Make sure you read to the end.

[Will Herrington @willkidney]

🌞11 fab. large#SGLT2i trials 🥰
🌧 184 subsidiary papers ☹️.
☔️ Need an antidote 2 dredged data?🤫
🌈 Try this comprehensive #SGLT2i #meta-analysis - distilled data for all busy clinicians.
🎁 from ⁦⁦@Oxford_NDPH⁩
#Flozinate with confidence🙂 https://t.co/yK2Glb3UA6

[The ICR @ICR_London]

Hi everyone! I'm Meg a first year PhD student at @MarcoGerlinger 's lab in Chelsea! So excited to take everyone through some of exciting research happening in our lab!🎉

[Martin Landray @MartinLandray]

RECOVERY:

1 year summarised in 1 minute

👇

[Martin Landray @MartinLandray]

RECOVERY Pre-print:

Convalescent plasma does not improve survival in patients hospitalised with COVID-19 in this randomised controlled trial involving 11,558 patients:

https://t.co/36YZwJNY3Q